npj Parkinson's Disease (Apr 2023)
Elevated urine BMP phospholipids in LRRK2 and VPS35 mutation carriers with and without Parkinson’s disease
- Sara Gomes,
- Alicia Garrido,
- Francesca Tonelli,
- Donina Obiang,
- Eduardo Tolosa,
- Maria José Martí,
- Javier Ruiz-Martínez,
- Ana Vinagre-Aragón,
- Haizea Hernandez-Eguiazu,
- Ioana Croitoru,
- Vicky L. Marshall,
- Theresa Koenig,
- Christoph Hotzy,
- Frank Hsieh,
- Marianna Sakalosh,
- Elizabeth Tengstrand,
- Shalini Padmanabhan,
- Kalpana Merchant,
- Christof Bruecke,
- Walter Pirker,
- Alexander Zimprich,
- Esther Sammler
Affiliations
- Sara Gomes
- Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee
- Alicia Garrido
- Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari
- Francesca Tonelli
- Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee
- Donina Obiang
- Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari
- Eduardo Tolosa
- Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari
- Maria José Martí
- Parkinson’s Disease and Movement Disorders Unit, Institut Clínic de Neurociències, Hospital Clinic Universitari
- Javier Ruiz-Martínez
- Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)
- Ana Vinagre-Aragón
- Hospital Universitario Donostia
- Haizea Hernandez-Eguiazu
- Group of Neurodegenerative Diseases, Biodonostia Research Institute
- Ioana Croitoru
- Hospital Universitario Donostia
- Vicky L. Marshall
- Neurology, Queen Elizabeth University Hospital, Institute of Neurological Sciences
- Theresa Koenig
- Department of Neurology, Medical University of Vienna
- Christoph Hotzy
- Department of Neurology, Medical University of Vienna
- Frank Hsieh
- Nextcea, Inc. 500 West Cummings Park, Suite 4550
- Marianna Sakalosh
- Nextcea, Inc. 500 West Cummings Park, Suite 4550
- Elizabeth Tengstrand
- Nextcea, Inc. 500 West Cummings Park, Suite 4550
- Shalini Padmanabhan
- The Michael J. Fox Foundation for Parkinson’s Research
- Kalpana Merchant
- Northwestern University Feinberg School of Medicine
- Christof Bruecke
- Department of Neurology, Medical University of Vienna
- Walter Pirker
- Department of Neurology, Klinik Ottakring
- Alexander Zimprich
- Department of Neurology, Medical University of Vienna
- Esther Sammler
- Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, University of Dundee
- DOI
- https://doi.org/10.1038/s41531-023-00482-4
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 4
Abstract
Abstract Elevated urine bis(monoacylglycerol)phosphate (BMP) levels have been found in gain-of-kinase function LRRK2 G2019S mutation carriers. Here, we have expanded urine BMP analysis to other Parkinson’s disease (PD) associated mutations and found them to be consistently elevated in carriers of LRRK2 G2019S and R1441G/C as well as VPS35 D620N mutations. Urine BMP levels are promising biomarkers for patient stratification and potentially target engagement in clinical trials of emerging targeted PD therapies.
